Sign in

Publications

Search in 13054 publications:

Reset RSS
Time frame
13054 Publication(s)
Feb 19, 2019
Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study
Schmid S, Jochum W, Demmer I, Foerbs D, Janthur W, Wannesson L, Rothschild S, Pless M, Gautschi O, Britschgi C, Aeppli S, Klingbiel D, Früh M. Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study. Lung Cancer 2019; 130:149-155.
Feb 19, 2019
Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study
Feb 19, 2019

Lung Cancer 2019; 130:149-155

Schmid Sabine, Jochum Wolfram, Demmer I, Foerbs D, Janthur W, Wannesson L, Rothschild S, Pless M, Gautschi O, Britschgi C, Aeppli Stefanie, Klingbiel D, Früh Martin

more
Feb 18, 2019
Soluble delta-like 1 homolog decreases in patients with acromegaly following pituitary surgery: A potential mediator of adipogenesis suppression by growth hormone?
Sze L, Tschopp O, Neidert M, Bernays R, Ghirlanda C, Zwimpfer C, Wiesli P, Schmid C. Soluble delta-like 1 homolog decreases in patients with acromegaly following pituitary surgery: A potential mediator of adipogenesis suppression by growth hormone?. Growth Horm IGF Res 2019; 45:20-24.
Feb 18, 2019
Soluble delta-like 1 homolog decreases in patients with acromegaly following pituitary surgery: A potential mediator of adipogenesis suppression by growth hormone?
Feb 18, 2019

Growth Horm IGF Res 2019; 45:20-24

Sze Lisa, Tschopp Oliver, Neidert Marian Christoph, Bernays René L, Ghirlanda Claudia, Zwimpfer Cornelia, Wiesli Peter, Schmid Christoph

more
Feb 18, 2019
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma
Amodio N, Tagliaferri P, Neri A, Driessen C, Rossi M, Ronchetti D, Caracciolo D, Federico C, Agosti V, Botta C, Gallo Cantafio M, Tassone P. Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma. Cancers (Basel) 2019; 11
Feb 18, 2019
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma
Feb 18, 2019

Cancers (Basel) 2019; 11

Amodio Nicola, Tagliaferri Pierosandro, Neri Antonino, Driessen Christoph, Rossi Marco, Ronchetti Domenica, Caracciolo Daniele, Federico Cinzia, Agosti Valter, Botta Cirino, Gallo Cantafio Maria Eugenia, Tassone Pierfrancesco

more
Feb 15, 2019
Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
Hanker A, Castellino S, Joensuu H, Huober J, Brase J, Majjaj S, Brohée S, Venet D, Brown D, Baselga J, Piccart M, Sotiriou C, Groseclose M, Becker J, Garrett J, Estrada M, Moore P, Ericsson P, Koch J, Langley E, Singh S, Kim P, Frampton G, Sanford E, Owens P, Arteaga C. Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2. Clin Cancer Res 2019; 25:1434.
Feb 15, 2019
Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
Feb 15, 2019

Clin Cancer Res 2019; 25:1434

Hanker Ariella B, Castellino Stephen, Joensuu Heikki, Huober Jens, Brase Jan C, Majjaj Samira, Brohée Sylvain, Venet David, Brown David, Baselga José, Piccart Martine, Sotiriou Christos, Groseclose M Reid, Becker Jennifer, Garrett Joan T, Estrada Mónica Valeria, Moore Preston D, Ericsson Paula González, Koch James P, Langley Emma, Singh Sharat, Kim Phillip S, Frampton Garrett M, Sanford Eric, Owens Philip, Arteaga Carlos L

more
Feb 15, 2019
No impact of exacerbation frequency and severity on the physical activity decline in COPD: a long-term observation
Sievi N, Kohler M, Thurnheer R, Leuppi J, Irani S, Frey M, Brutsche M, Brack T, Clarenbach C. No impact of exacerbation frequency and severity on the physical activity decline in COPD: a long-term observation. Int J Chron Obstruct Pulmon Dis 2019; 14:431-437.
Feb 15, 2019
No impact of exacerbation frequency and severity on the physical activity decline in COPD: a long-term observation
Feb 15, 2019

Int J Chron Obstruct Pulmon Dis 2019; 14:431-437

Sievi Noriane A, Kohler Malcolm, Thurnheer Robert, Leuppi Joerg D, Irani Sarosh, Frey Martin, Brutsche Martin, Brack Thomas, Clarenbach Christian F

more
Feb 14, 2019
A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer
Trefny M, Savic S, Jermann P, Alborelli I, Schaub S, Stenner F, Früh M, Trajanoski Z, Flatz L, Mertz K, Zippelius A, Geier F, Thommen D, Rothschild S, Uhlenbrock F, Rieder D, Kasenda B, Stanczak M, Berner F, Kashyap A, Kaiser M, Herzig P, Poechtrager S, Läubli H. A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer. Clin Cancer Res 2019; 25:3026-3034.
Feb 14, 2019
A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer
Feb 14, 2019

Clin Cancer Res 2019; 25:3026-3034

Trefny Marcel P, Savic Spasenija, Jermann Philip, Alborelli Ilaria, Schaub Stefan, Stenner Frank, Früh Martin, Trajanoski Zlatko, Flatz Lukas, Mertz Kirsten D, Zippelius Alfred, Geier Florian, Thommen Daniela S, Rothschild Sacha I, Uhlenbrock Franziska, Rieder Dietmar, Kasenda Benjamin, Stanczak Michal A, Berner Fiamma, Kashyap Abhishek S, Kaiser Monika, Herzig Petra, Poechtrager Severin, Läubli Heinz

more
Feb 14, 2019
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial
Neurooncology Working Group of the German Cancer Society, Simon M, Tonn J, Stummer W, Schaub C, Weller J, Kebir S, Schäfer N, Stuplich M, Vatter H, Misch M, Keil V, Nelles M, Glas M, Coch C, Pietsch T, Hattingen E, Schmid M, Fimmers R, Weller M, Wick W, Coenen M, Urbach H, Vajkoczy P, Galldiks N, Bullinger L, Goldbrunner R, Grauer O, Krex D, Kortmann R, Hau P, Sabel M, Schlegel U, Steinbach J, Mack F, Tzaridis T, Schnell O, Bähr O, Renovanz M, Weyerbrock A, Brehmer S, Suchorska B, Schmidt-Graf F, Ringel F, Kowalski T, Tabatabai G, Seidel C, Uhl M, Herrlinger U. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Lancet 2019; 393:678-688.
Feb 14, 2019
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial
Feb 14, 2019

Lancet 2019; 393:678-688

Neurooncology Working Group of the German Cancer Society, Simon Matthias, Tonn Jörg-Christian, Stummer Walter, Schaub Christina, Weller Johannes, Kebir Sied, Schäfer Niklas, Stuplich Moritz, Vatter Hartmut, Misch Martin, Keil Vera C, Nelles Michael, Glas Martin, Coch Christoph, Pietsch Torsten, Hattingen Elke, Schmid Matthias, Fimmers Rolf, Weller Michael, Wick Wolfgang, Coenen Martin, Urbach Horst, Vajkoczy Peter, Galldiks Norbert, Bullinger Lars, Goldbrunner Roland, Grauer Oliver, Krex Dietmar, Kortmann Rolf-Dieter, Hau Peter, Sabel Michael, Schlegel Uwe, Steinbach Joachim Peter, Mack Frederic, Tzaridis Theophilos, Schnell Oliver, Bähr Oliver, Renovanz Miriam, Weyerbrock Astrid, Brehmer Stefanie, Suchorska Bogdana, Schmidt-Graf Friederike, Ringel Florian, Kowalski Thomas, Tabatabai Ghazaleh, Seidel Clemens, Uhl Martin, Herrlinger Ulrich

more
Feb 14, 2019
No difference in joint awareness after TKA: a matched-pair analysis of a classic implant and its evolutional design
Behrend H, Zdravkovic V, Bösch M, Hochreiter B. No difference in joint awareness after TKA: a matched-pair analysis of a classic implant and its evolutional design. Knee Surg Sports Traumatol Arthrosc 2019; 27:2124-2129.
Feb 14, 2019
No difference in joint awareness after TKA: a matched-pair analysis of a classic implant and its evolutional design
Feb 14, 2019

Knee Surg Sports Traumatol Arthrosc 2019; 27:2124-2129

Behrend Henrik, Zdravkovic Vilijam, Bösch Marco, Hochreiter Bettina

more
Feb 13, 2019
A Rare Case of Localized Argyria on the Face
Isak V, Beerli T, Cozzio A, Flatz L. A Rare Case of Localized Argyria on the Face. Case Rep Dermatol 2019; 11:23-27.
Feb 13, 2019
A Rare Case of Localized Argyria on the Face
Feb 13, 2019

Case Rep Dermatol 2019; 11:23-27

Isak Verena, Beerli Tobias, Cozzio Antonio, Flatz Lukas

more
Feb 13, 2019
Replacement of the Nasal Dorsum with a Diced Cartilage Glue Graft
Tasman A. Replacement of the Nasal Dorsum with a Diced Cartilage Glue Graft. Facial Plast Surg 2019; 35:53-57.
Feb 13, 2019
Replacement of the Nasal Dorsum with a Diced Cartilage Glue Graft
Feb 13, 2019

Facial Plast Surg 2019; 35:53-57

Tasman Abel-Jan

more
Feb 13, 2019
Decision Making in Oncology
Putora P. Decision Making in Oncology. JCO Clin Cancer Inform 2019; 3:1-2.
Feb 13, 2019
Decision Making in Oncology
Feb 13, 2019

JCO Clin Cancer Inform 2019; 3:1-2

Putora Paul Martin

more
Feb 13, 2019
Torque-planning errors affect the perception of object properties and sensorimotor memories during object manipulation in uncertain grasp situations
Schneider T, Buckingham G, Hermsdörfer J. Torque-planning errors affect the perception of object properties and sensorimotor memories during object manipulation in uncertain grasp situations. J Neurophysiol 2019; 121:1289-1299.
Feb 13, 2019
Torque-planning errors affect the perception of object properties and sensorimotor memories during object manipulation in uncertain grasp situations
Feb 13, 2019

J Neurophysiol 2019; 121:1289-1299

Schneider Thomas, Buckingham Gavin, Hermsdörfer Joachim

more
Feb 13, 2019
Challenges of helicopter mountain rescue missions by human external cargo: need for physicians onsite and comprehensive training
Pietsch U, Strapazzon G, Ambühl D, Lischke V, Rauch S, Knapp J. Challenges of helicopter mountain rescue missions by human external cargo: need for physicians onsite and comprehensive training. Scand J Trauma Resusc Emerg Med 2019; 27:17.
Feb 13, 2019
Challenges of helicopter mountain rescue missions by human external cargo: need for physicians onsite and comprehensive training
Feb 13, 2019

Scand J Trauma Resusc Emerg Med 2019; 27:17

Pietsch Urs, Strapazzon Giacomo, Ambühl Dimitri, Lischke Volker, Rauch Simon, Knapp Jürgen

more
Feb 12, 2019
Characterizing ipsilateral thalamic diaschisis in symptomatic cerebrovascular steno-occlusive patients.
Hendrik Bas van Niftrik C, Sebök M, Muscas G, Piccirelli M, Serra C, Krayenbühl N, Pangalu A, Bozinov O, Luft A, Stippich C, Regli L, Fierstra J. Characterizing ipsilateral thalamic diaschisis in symptomatic cerebrovascular steno-occlusive patients. J Cereb Blood Flow Metab 2019; 40:563-573.
Feb 12, 2019
Characterizing ipsilateral thalamic diaschisis in symptomatic cerebrovascular steno-occlusive patients.
Feb 12, 2019

J Cereb Blood Flow Metab 2019; 40:563-573

Hendrik Bas van Niftrik Christiaan, Sebök Martina, Muscas Giovanni, Piccirelli Marco, Serra Carlo, Krayenbühl Niklaus, Pangalu Athina, Bozinov Oliver, Luft Andreas, Stippich Christoph, Regli Luca, Fierstra Jorn

more
Feb 11, 2019
Differenzialdiagnose des Fersenschmerzes
Potocnik P, Hochreiter B, Harrasser N, Meester J, Toepfer A. Differenzialdiagnose des Fersenschmerzes. Der Orthopäde 2019; 48:261-280.
Feb 11, 2019
Differenzialdiagnose des Fersenschmerzes
Feb 11, 2019

Der Orthopäde 2019; 48:261-280

Potocnik Primoz, Hochreiter Bettina, Harrasser Norbert, Meester Jan, Toepfer Andreas

more
Feb 11, 2019
Targeting the CALCB/RAMP1 axis inhibits growth of Ewing sarcoma
Dallmayer M, Sannino G, Bach H, Kirchner T, Marchetto A, Orth M, Gerke J, Romero-Pérez L, Wehweck F, Cidre-Aranaz F, Stein S, Knott M, Musa J, Hölting T, Baldauf M, Alba Rubio R, Ohmura S, Li J, Grünewald T. Targeting the CALCB/RAMP1 axis inhibits growth of Ewing sarcoma. Cell Death Dis 2019; 10:116.
Feb 11, 2019
Targeting the CALCB/RAMP1 axis inhibits growth of Ewing sarcoma
Feb 11, 2019

Cell Death Dis 2019; 10:116

Dallmayer Marlene, Sannino Giuseppina, Bach Horacio, Kirchner Thomas, Marchetto Aruna, Orth Martin F, Gerke Julia S, Romero-Pérez Laura, Wehweck Fabienne S, Cidre-Aranaz Florencia, Stein Stefanie, Knott Max M L, Musa Julian, Hölting Tilman L B, Baldauf Michaela, Alba Rubio Rebeca, Ohmura Shunya, Li Jing, Grünewald Thomas G P

more
Feb 8, 2019
First clinico-pathological evidence of a non PSMA-related uptake mechanism for Ga-PSMA-11 in salivary glands
Rupp N, Schibli R, Eberli D, Huber G, Morand G, Messerli M, Ferraro D, Mühlematter U, Müller J, Töpfer A, Lenggenhager D, Pizzuto D, Umbricht C, Burger I. First clinico-pathological evidence of a non PSMA-related uptake mechanism for Ga-PSMA-11 in salivary glands. J Nucl Med 2019
Feb 8, 2019
First clinico-pathological evidence of a non PSMA-related uptake mechanism for Ga-PSMA-11 in salivary glands
Feb 8, 2019

J Nucl Med 2019

Rupp Niels J, Schibli Roger, Eberli Daniel, Huber Gerhard, Morand Grégoire B, Messerli Michael, Ferraro Daniela A, Mühlematter Urs Jacob, Müller Julian, Töpfer Antonia, Lenggenhager Daniela, Pizzuto Daniele A, Umbricht Christoph A, Burger Irene A

more
Feb 8, 2019
Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer
Papachristofilou A, Kallen K, Fotin-Mleczek M, Schröder A, Scheel B, Muth A, Seibel T, Stosnach C, Doener F, Hong H, Koch S, Gnad-Vogt U, Griesinger F, Geißler M, Bischoff H, Hipp M, Klinkhardt U, Früh M, Sebastian M, Weiss C, Pless M, Cathomas R, Hilbe W, Pall G, Wehler T, Alt J, Zippelius A. Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer. J Immunother Cancer 2019; 7:38.
Feb 8, 2019
Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer
Feb 8, 2019

J Immunother Cancer 2019; 7:38

Papachristofilou Alexandros, Kallen Karl-Josef, Fotin-Mleczek Mariola, Schröder Andreas, Scheel Birgit, Muth Anke, Seibel Tobias, Stosnach Claudia, Doener Fatma, Hong Henoch S, Koch Sven D, Gnad-Vogt Ulrike, Griesinger Frank, Geißler Michael, Bischoff Helge, Hipp Madeleine M, Klinkhardt Ute, Früh Martin, Sebastian Martin, Weiss Christian, Pless Miklos, Cathomas Richard, Hilbe Wolfgang, Pall Georg, Wehler Thomas, Alt Jürgen, Zippelius Alfred

more
Feb 5, 2019
Characterization and in vitro phase I microsomal metabolism of designer benzodiazepines: An update comprising flunitrazolam, norflurazepam, and 4'-chlorodiazepam (Ro5-4864)
Moosmann B, Bisel P, Westphal F, Wilde M, Kempf J, Angerer V, Auwärter V. Characterization and in vitro phase I microsomal metabolism of designer benzodiazepines: An update comprising flunitrazolam, norflurazepam, and 4'-chlorodiazepam (Ro5-4864). Drug Test Anal 2019; 11:541-549.
Feb 5, 2019
Characterization and in vitro phase I microsomal metabolism of designer benzodiazepines: An update comprising flunitrazolam, norflurazepam, and 4'-chlorodiazepam (Ro5-4864)
Feb 5, 2019

Drug Test Anal 2019; 11:541-549

Moosmann Björn, Bisel Philippe, Westphal Folker, Wilde Maurice, Kempf Jürgen, Angerer Verena, Auwärter Volker

more
Feb 5, 2019
Type I interferon induces CXCL13 to support ectopic germinal center formation
Denton A, Good-Jacobson K, Groom J, Ludewig B, Mörbe U, Mabbott N, Lafouresse F, Bradford B, Carr E, Innocentin S, Linterman M. Type I interferon induces CXCL13 to support ectopic germinal center formation. J Exp Med 2019
Feb 5, 2019
Type I interferon induces CXCL13 to support ectopic germinal center formation
Feb 5, 2019

J Exp Med 2019

Denton Alice E, Good-Jacobson Kim L, Groom Joanna R, Ludewig Burkhard, Mörbe Urs, Mabbott Neil A, Lafouresse Fanny, Bradford Barry M, Carr Edward J, Innocentin Silvia, Linterman Michelle A

more

We use cookies and tracking technologies according to our privacy policy to provide you with the best possible web experience. To the privacy policy